July 30, 2010 - Some exciting news was released today! Bio-Path Holdings, Inc. is a company out of Houston, Texas that works with M.D. Anderson. M.D. Anderson is a hospital famous for helping cancer patients and hosting many different scientific trials. Last year we actually submitted all of Eric's paperwork to them and took the steps necessary to enroll him in a clinical trial down there.
Well, this company was announced today that they have developed a new AML drug that has made it to Phase I clinical trials. The drug, called "Liposomal Grb-2 Cancer Drug Candidate", works by
Ras gene - A gene in which excessive activity or mutations are associated with many types of cancer, aka proto-oncogene. Mutations of Ras genes occur in 15–30% of acute myeloid leukaemia patients
Tyrosine Kinase - an enzyme that can transfer a phosphate group from ATP to a tyrosine residue in a protein. Tyrosine kinases are important elements of signal transduction pathways that transmit extracellular signals to the inside of the cell, thereby controlling cellular events such as proliferation, differentiation, and cell death. Abnormalities in tyrosine kinases are common in AML.
Antisense drugs stop a particular gene from producing the protein for which it holds the recipe.
See the below article for full details.
Bio-Path Holdings Announces Dosing of First Patient in a Phase I Clinical Trial of its Liposomal Grb-2 Cancer Drug Candidate
FOR IMMEDIATE RELEASE
July 29, 2010 HOUSTON, TX – Bio-Path Holdings, Inc., (OTC BB: BPTH) (“Bio-Path”), a biotechnology company with drug development operations in Houston, Texas, announced today that the first patient has been dosed in a Phase I study of its cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP-100-1.01), in patients with Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL) or Myelodysplastic Syndrome (MDS). Bio-Path is developing a neutral lipid-based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules), a delivery technology that forms microscopic-sized vehicles to safely deliver these drugs to their intended target cancer cells.
Growth factor receptor bound protein-2 (Grb-2) is an adaptor protein that has shown to be involved with several types of cancer. The main function of Grb-2 is to link activated tyrosine kinase to Ras activation. The Grb-2 gene is mapped to the human chromosome region known to be duplicated in leukemia and solid tumors, including breast cancer. The strategy employed using Bio-Path’s L-Grb-2 antisense drug candidate is to inhibit Grb-2 expression in the cell utilizing liposome-incorporated, nuclease-resistant antisense oligonucleotides specific for Grb-2 messenger-RNA. The Grb-2 antisense molecule blocks binding of ribosomes to the Grb-2 mRNA, thereby impairing Grb-2 protein production.
July 28, 2010 - The results from Eric's bone marrow biopsy last week came in today and they are clean!
July 22, 2010 - Eric had another follow-up bone marrow biopsy performed at Froedtert Hospital today. (click here for his description of the procedure) Eric's been looking very healthy, so we expect the results next week to come back clean. He has been in remission for nearly 8 months now.